Uncovering Factors Related to Pancreatic Beta-Cell Function

Aoife M. Curran¹, Miriam F. Ryan¹, Elaine Drummond¹, Eileen R. Gibney¹, Michael J. Gibney¹, Helen M. Roche¹,², Lorraine Brennan¹*

¹ Institute of Food and Health, School of Agriculture and Food Science, University College Dublin, Dublin, Republic of Ireland, ² Nutrigenomics Research Group, UCD Conway Institute of Biomolecular and Biomedical Research and UCD Institute of Food and Health, School of Public Health, Physiotherapy and Sports Science, University College Dublin, Belfield, Dublin 4, Republic of Ireland

* lorraine.brennan@ucd.ie

Abstract

Aim

The incidence of type 2 diabetes has increased rapidly on a global scale. Beta-cell dysfunction contributes to the overall pathogenesis of type 2 diabetes. However, factors contributing to beta-cell function are not clear. The aims of this study were (i) to identify factors related to pancreatic beta-cell function and (ii) to perform mechanistic studies in vitro.

Methods

Three specific measures of beta-cell function were assessed for 110 participants who completed an oral glucose tolerance test as part of the Metabolic Challenge Study. Anthropometric and biochemical parameters were assessed as potential modulators of beta-cell function. Subsequent in vitro experiments were performed using the BRIN-BD11 pancreatic beta-cell line. Validation of findings were performed in a second human cohort.

Results

Waist-to-hip ratio was the strongest anthropometric modulator of beta-cell function, with beta-coefficients of -0.33 (p = 0.001) and -0.30 (p = 0.002) for beta-cell function/homeostatic model assessment of insulin resistance (HOMA-IR), and disposition index respectively. Additionally, the resistin-to-adiponectin ratio (RA index) emerged as being strongly associated with beta-cell function, with beta-coefficients of -0.24 (p = 0.038) and -0.25 (p = 0.028) for beta-cell function/HOMA-IR, and disposition index respectively. Similar results were obtained using a third measure for beta-cell function.

In vitro experiments revealed that the RA index was a potent regulator of acute insulin secretion where a high RA index (20ng ml⁻¹ resistin, 5nmol l⁻¹ g-adiponectin) significantly decreased insulin secretion whereas a low RA index (10ng ml⁻¹ resistin, 10nmol l⁻¹ g-adiponectin) significantly increased insulin secretion. The RA index was successfully validated in a second human cohort with beta-coefficients of -0.40 (p = 0.006) and -0.38 (p = 0.008) for beta-cell function/ HOMA-IR, and disposition index respectively.
Conclusions
Waist-to-hip ratio and RA index were identified as significant modulators of beta-cell function. The ability of the RA index to modulate insulin secretion was confirmed in mechanistic studies. Future work should identify strategies to alter the RA index.

Introduction
The prevalence of type 2 diabetes (T2D) has increased rapidly on an international scale, with pancreatic beta-cell dysfunction and failure at the core of its development [1]. Where hyperglycaemia exists, pancreatic beta-cells must function to a greater capacity in order to produce more insulin to maintain glucose homeostasis [2]. Beta-cells have an ability to functionally adapt to allow for this compensatory response of further insulin production. Beta-cell dysfunction is commonly seen in T2D, where ‘compensation’ of the beta-cells to produce insulin, often due to insulin resistance, leads to the gradual failure of beta-cells [3]. With this in mind, there is a need to investigate factors related to pancreatic beta-cell function in humans.

Glucose stimulates insulin secretion, triggering and amplifying signals in pancreatic beta-cells [4–6]. Challenge tests such as the oral glucose tolerance test (OGTT) have been used to investigate how effective individuals are at maintaining glucose homeostasis, thus assessing beta-cell function [7]. Progression into T2D status can be categorised by examining alterations in metabolic parameters and beta-cell function. Weir & Bonner-Weir proposed five stages of evolving beta-cell dysfunction during the progression into T2D [8]. Stage 1 is described as ‘compensation’, where overweight or obese individuals with a degree of insulin resistance have to increase insulin secretion from beta-cells in order to maintain homeostasis. Stage 2 occurs where fasting blood glucose levels range between 5–7.3mmol/L, which represents ‘beta-cell adaptation’. Stage 3 represents ‘early decompensation’ in which glucose levels rise above 7.3mmol/L, and from this progress rapidly towards a glucose level representative of stage 4, known as ‘stable decompensation’, where levels typically range between 16–20mmol/L. Individuals progressing towards T2D can remain in stage 2 for many years, but when beta-cell mass becomes insufficient at an important point, glucose levels rise rapidly to stage 4. Lastly, stage 5 represents ‘severe decompensation’ and extreme beta-cell failure with advancement to ketosis, with blood glucose levels above 22mmol/L. Movement between stages 1–4 can be in either direction, with diet and exercise interventions having strong potential to return individuals back to stage 2 [8].

It is important to identify parameters which influence the function of beta-cells, in order to optimise beta-cell functionality and potentially identify markers of disease progression or targets for intervention. Body mass index (BMI) and an increased energy intake are recognised as major risk factors for conditions associated with beta-cell dysfunction, and although the evidence of a direct effect of BMI on pancreatic beta-cell function is still largely undefined, the association between BMI and T2D has been well established [9–12]. Strong evidence also exists that an excess of visceral fat is closely related to insulin resistance and T2D risk [13]. The above studies did not have beta-cell dysfunction as their primary aim; therefore further research is needed to determine the exact phenotypic and biochemical parameters that influence specific measures of beta-cell function. A number of recent studies have highlighted a link between beta-cell function and high density lipoprotein (HDL) cholesterol [14–16]. Several studies have found links between certain anthropometric and biochemical parameters associated with T2D, with fewer studies examining the determinants of specific measures of beta-cell function in human cohorts. Beta-cell dysfunction is at the core of T2D, therefore it is paramount to
understand factors which influence beta-cell function. In contrast to insulin resistance, beta-cell dysfunction continues to be difficult to measure and monitor, due to factors such as inaccessibility to the endocrine pancreas and incretin effects [17]. There is a clear need for the identification of markers that could be assessed in a fasting biological sample, to allow for the assessment of beta-cell function.

Therefore, the aim of this study was to investigate and identify potential factors related to beta-cell function measures in a human cohort and to further investigate these in vitro where possible.

Materials and Methods

Study population

This research focuses on data obtained from the Metabolic Challenge (MECHE) study which is part of a national research program by the Joint Irish Nutrigenomics Organisation, as previously described [18]. The MECHE study recruited 214 healthy participants aged between 18–60 years. Individuals were informed about the purpose of the study and the experimental procedures, prior to giving written consent. Good health was defined as the absence of any known chronic or infectious disease and this was verified by a number of fasting blood tests. Details of the study have been published elsewhere [18–21]. Ethical approval was obtained from the Research Ethics Committee at University College Dublin (LS-08-43-Gibney-Ryan) and the study was performed according to the Declaration of Helsinki.

Baseline blood samples were collected on the morning of the study visits following an overnight fast. Participants underwent an OGTT according to the guidelines set by the World Health Organisation/International Diabetes Federation. Venous blood samples were taken before (0 min) and during the OGTT at set time-points (10, 20, 30, 60, 90 and 120 min), and serum and plasma samples were collected as previously described [18–21].

Details of the analytes and methods used are previously reported, along with the measurement of cytokines and hormones [19]. Lipidomic analysis was performed on serum samples (BIOCRATES Life Sciences AG, Innsbruck, Austria), and ceramides were measured using an in-house lipid assay as previously described [18].

For the present study, participants from the MECHE study who underwent an OGTT and who had valid glucose and insulin data at time-points 0 and 30 min were included (n = 110). Their baseline demographic and biochemical parameters were used for analysis. The validation cohort, (Food for Health (FHI) cohort) comprised of 47 healthy overweight and obese participants, with a mean age of 53 years and a mean BMI of 32.1 kg m−2.

Measurement of beta-cell function and RA index

Beta-cell function was calculated as the ratio of the incremental insulin to glucose response over the first 30 min of the OGTT (ΔInsulin30/ΔGlucose30) and three different measures were employed. Firstly, beta-cell function was adjusted for homeostatic model assessment of insulin resistance (HOMA-IR) ((ΔInsulin30/ΔGlucose30)/HOMAIR). Secondly, the oral disposition index (DI), which takes into account insulin sensitivity, was calculated for all participants D_{Insulin}^{30} = D_{Glucose}^{30} \left( \frac{1}{\text{fastingInsulin}} \right) [22]. Thirdly, beta-cell function was calculated and adjusted for the Matsuda Index 10000/√(Glucose0 × Insulin0 × Glucose_{120} × Insulin_{120}) (, where glucose is in mg dl⁻¹ and insulin in iU ml⁻¹ [23]. Additionally, C-peptide data was substituted for insulin data for the DI, for the beta-cell function (ΔCpeptide_{30}/ΔGlucose_{30}) and beta-cell function adjusted for the Matsuda Index (ΔCpeptide_{30}/ΔGlucose_{30}) × Matsuda Index,.
A ratio of resistin ($R_0$) to adiponectin ($A_0$) (RA index) was formulated as follows:

$$RA \text{ index} = \frac{R_0}{A_0}$$

Where: $R_0 =$ fasting plasma resistin levels (ng ml$^{-1}$) and $A_0 =$ fasting serum total adiponectin levels (μg ml$^{-1}$)

Cell culture and treatment

All chemicals were purchased from Sigma-Aldrich Ireland unless otherwise stated. Culture media and its related components were purchased from Gibco (Glasgow, UK). The BRIN-BD11 cell line was used in this study [24] and was maintained as previously described [25].

For experimental treatments, cells were seeded at a density of 1.5 x 10$^5$ cells per well in a 24 well plate for insulin secretion assays. Cells were allowed to attach for 24 h before being treated with recombinant rat resistin (Cambridge Biosciences, Cambridge, UK) or rat GACRP30/Adiponectin (Sigma-Aldrich) or ratios of both, for 24 h. Concentrations of 10–20ng ml$^{-1}$ of resistin and 5–20nmol l$^{-1}$ of globular (g) adiponectin were used. Concentrations were chosen in accordance with previous studies [26, 27]. Cells between passage 23–33 were used and all experiments were $n = 4$ unless otherwise stated.

Acute insulin secretion

Following the 24 h treatment period, the culture medium was removed and the cells were washed with phosphate buffered saline (PBS). The cells were then incubated with Krebs-Ringer bicarbonate (KRB) buffer (115mM NaCL, 1.28mM CaCl$_2$, 4.7mM KCl, 1.2mM KH$_2$PO$_4$, 1.2mM MgSO$_4$ 7H$_2$O, 10mM NaHC0$_3$, 5 gl$^{-1}$ BSA, all at pH 7.4) supplemented with 1.1mM glucose for 40 min. The media was then replaced with KRB buffer containing 16.7mM glucose + 10mM alanine, for 20 min. Following this, the samples were transferred to Eppendorfs and centrifuged, before removing the supernatant and assaying for insulin content using a Mercodia Ultrasensitive Rat Insulin ELISA kit (Mercodia AB, Uppsala, Sweden).

Measurement of mitochondrial membrane potential, intracellular calcium and plasma membrane potential

In order to measure mitochondrial membrane potential, a protocol based on Rhodamine fluorescence as described by Wallace et al was followed [25]. Cells were treated for 24 h with high and low RA index. Fluorescence was measured over a period of 150 seconds collecting data every 3 seconds, with injection of glucose to a final concentration of 16.7mM + 10mM alanine at 50 seconds.

Intracellular calcium was analysed using the FLIPR Calcium 4 assay kit (R8141 Bulk Kit Molecular Devices), as described by Wallace et al [25]. Cells were treated for 24 h with high and low RA index. Fluorescence was then measured in a Flexstation, with readings every 2.5 seconds for 10 min. Cells were stimulated at 100 seconds with 16.7mM glucose + 10mM alanine).

Plasma membrane potential was also determined. Following 24 hour treatment with a high and low RA index, media was removed and the cells were incubated with 100μl of 2.2mM glucose KRB buffer and 100μl of loading dye (FLIPR blue membrane potential buffer (Molecular Devices)) for 20 min. Fluorimetric data was acquired on the Flexstation with an excitation wavelength of 530nm and an emission wavelength of 565nm. The Flexstation was set to run for
350 seconds, collecting data at 2.5 second intervals, with stimulation of the cells (16.7 mM glucose + 10 mM alanine) occurring at 100 seconds.

Gene expression analysis

Cells were seeded in 6 well plates and allowed to reach 80% confluence before treatment with high RA index and low RA index for 24 h. Total RNA was extracted using TRIzol reagent (Invitrogen). Reverse transcription of 2 μg of total RNA was carried out using random primers and SuperScript II (Invitrogen by Life Technologies). Samples were incubated in a PCR incubator for 25°C for 10 min, 42°C for 50 min and 70°C for 15 min. The expression of Pancreatic and duodenal homeobox 1 (PDX1), Insulin receptor (INSR), Adiponectin receptor 1 (ADIPOR1) and Adiponectin receptor 2 (ADIPOR2) were investigated by real time PCR on an Applied Biosystems 7900HT fast real-time PCR system using TaqMan gene-specific assays (PDX1 (assay Rn00755591_m1), INSR (assay Rn00690703_m1), ADIPOR1 (assay Rn01483784_m1) and ADIPOR2 (assay Rn01463173_m1)). The results were normalised to beta-actin and cyclophilin A expression.

Statistical Analysis

Analysis was carried out using IBM SPSS Statistics V.20. Data are expressed as means ± standard deviation. Linear regression analysis was carried out to examine relationships between beta-cell function and various anthropometric and biochemical parameters. Statistical significance was evaluated using ANOVA with LSD and Bonferroni post-hoc tests. Significant differences were observed if P ≤ 0.05. For gene expression analysis, primary analysis was carried out using Sequence Detection Software (SDS) 2.4, and secondary analysis used the software package Data Assist 3.01.

Results

Study population

Analysis was performed on a total of 110 participants who underwent an OGTT. Baseline characteristics are presented in Table 1. An equal gender balance existed with 55 males and 55 females. The mean body mass index was 25.3 kg m⁻², which lies at the lower end of the overweight BMI category (25.0 – 29.9 kg m⁻²).

Identification of factors related to beta-cell function

Gender had no significant relationship with beta-cell function measures. Investigation into the effect of BMI revealed that as BMI increased, beta-cell function decreased (Table 2). As described in Table 3 waist-to-hip ratio was the strongest predictor of beta-cell function, with beta-coefficients of -0.33, -0.30, and -0.26 for beta-cell function/HOMA-IR, DI and beta-cell function adjusted for Matsuda index respectively. Further examination of the biochemical parameters revealed that the RA index had a strong relationship with beta-cell function with beta-coefficients of -0.24–0.25, and -0.25 for beta-cell function/HOMA-IR, DI and beta-cell function adjusted for Matsuda index respectively. C12:1(2H) was the strongest predictor of beta-cell function when ceramide data was examined. The list of ceramides analysed are present in S1 Table. Additionally, when C-peptide was used to calculate the DI and beta-cell function adjusted for the Matsuda index similar results emerged (S2 Table).

To validate the relationship between the RA index and beta-cell function, adiponectin and resistin concentrations were measured in a second cohort. This cohort, the Food for Health (FHI) cohort comprised of 47 healthy overweight and obese, slightly older participants and...
had a mean age of 53 years and a mean BMI of 32.1 kg m\(^{-2}\). The RA index was successfully validated in this second human cohort with beta coefficients of -0.395 (p = 0.006), -0.384 (p = 0.008) and -0.540 (p < 0.0001) for beta-cell function/ HOMA-IR, DI and beta-cell function adjusted for Matsuda index respectively (S3 Table).

**RA index modulates insulin secretion in pancreatic beta-cell line**

To assess the effects of exposure to resistin, g-adiponectin or a ratio of both, to pancreatic beta-cells, BRIN-BD11 cells were incubated with the adipokines for 24 h. There was no loss of cell viability during the incubation period. Following exposure to resistin no significant effect on insulin secretion was observed (Fig 1A). Conversely exposure to g-adiponectin resulted in a significant increase in insulin secretion at the higher concentration of 20nmol l\(^{-1}\) g-adiponectin (Fig 1B). A dose response study of various RA indexes was carried out (S1 Fig).

---

**Table 1. Baseline characteristics of MECHE cohort (n = 110).**

| Variable            | Mean ± S.D. |
|---------------------|-------------|
| Sex (m/f)           | 55/55       |
| Age (y)             | 32 ± 11     |
| Weight (kg)         | 76.65 ± 16.85 |
| BMI (kg m\(^{-2}\)) | 25.3 ± 5.3  |
| WHR                 | 0.85 ± 0.1  |
| BP SYS (mm Hg\(^{-1}\)) | 123.1 ± 12.9 |
| BP DIA (mm Hg\(^{-1}\)) | 74.7 ± 10.9 |
| Glucose (mmol l\(^{-1}\)) | 5.21 ± 0.56 |
| HDL cholesterol (mmol l\(^{-1}\)) | 1.34 ± 0.36 |
| TAG (mmol l\(^{-1}\)) | 1.05 ± 0.60 |
| Insulin (µIU ml\(^{-1}\)) | 8.48 ± 6.69 |
| HOMA-IR             | 2.00 ± 1.70 |
| Adiponectin (µg ml\(^{-1}\)) | 4.99 ± 3.07 |
| Resistin (ng ml\(^{-1}\)) | 4.56 ± 1.77 |

All values are means ± standard deviation. BMI, Body Mass Index; WHR, Waist to Hip Ratio; BP SYS, Systolic Blood Pressure; BP DIA, Diastolic Blood Pressure; HDL, High Density Lipoprotein cholesterol; TAG, triglycerides; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance

doi:10.1371/journal.pone.0161350.t001

had a mean age of 53 years and a mean BMI of 32.1 kg m\(^{-2}\). The RA index was successfully validated in this second human cohort with beta coefficients of -0.395 (p = 0.006), -0.384 (p = 0.008) and -0.540 (p < 0.0001) for beta-cell function/ HOMA-IR, DI and beta-cell function adjusted for Matsuda index respectively (S3 Table).

**RA index modulates insulin secretion in pancreatic beta-cell line**

To assess the effects of exposure to resistin, g-adiponectin or a ratio of both, on pancreatic beta-cells, BRIN-BD11 cells were incubated with the adipokines for 24 h. There was no loss of cell viability during the incubation period. Following exposure to resistin no significant effect on insulin secretion was observed (Fig 1A). Conversely exposure to g-adiponectin resulted in a significant increase in insulin secretion at the higher concentration of 20nmol l\(^{-1}\) g-adiponectin (Fig 1B). A dose response study of various RA indexes was carried out (S1 Fig). From this dose

---

**Table 2. Beta-cell function, resistin and adiponectin according to BMI categories.**

| BMI Categories (kg m\(^{-2}\)) | Group 1 (18–24.9 kg m\(^{-2}\)) | Group 2 (>25 kg m\(^{-2}\)) | P  |
|-------------------------------|---------------------------------|-----------------------------|----|
| (n = 60)                      | (n = 46)                        |                             |    |
| Beta-cell function/ HOMA-IR (pmol mmol\(^{-1}\)) | 14.26 ± 10.61                  | 9.55 ± 6.98                 | 0.04|
| Disposition index (pmol mmol\(^{-1}\)) | 3.22 ± 2.21                    | 2.48 ± 1.78                 | 0.07|
| Beta-cell function* Matsuda index | 14.50 ±13.38                   | 10.37 ± 11.94               | 0.11|
| Disposition index (C-Peptide) (nmol mmol\(^{-1}\)) | 3.07 ± 1.97                    | 2.31 ± 2.26                 | 0.07|
| Beta-cell function (C-peptide)* Matsuda index | 24.17 ± 20.06                  | 16.71 ± 16.77               | 0.05|
| Resistin (ng ml\(^{-1}\))     | 4.31 ± 1.54                    | 4.70 ± 1.98                 | 0.25|
| Adiponectin (µg ml\(^{-1}\))  | 5.73 ± 3.12                    | 3.55 ± 2.28                 | <0.001|

All values are means ± standard deviation. P-value determined using independent samples t-test (Significance level (P = <0.05)).

* indicates multiplication

doi:10.1371/journal.pone.0161350.t002
response data we chose the RA indexes that elicited the lowest and highest insulin secretion response. Following treatment with two different RA indexes, a high RA index (20ng ml\(^{-1}\) resistin, 5nmol l\(^{-1}\) g-adiponectin) significantly decreased insulin secretion whereas a low RA index (10ng ml\(^{-1}\) resistin, 10nmol l\(^{-1}\) g-adiponectin) significantly increased insulin secretion (Fig 1C). Interestingly at this concentration of adiponectin alone there was no significant increase in insulin secretion indicating the importance of the ratio.

Functional assays revealed that plasma membrane potential of cells treated with the low RA index was significantly greater in comparison to the control (no treatment). The high RA index displayed significantly lower plasma membrane potential compared to the low RA index (Fig 2). No significant differences were seen between treatments in mitochondrial membrane assays or intracellular calcium assays (S2 and S3 Figs).

Real time PCR analysis revealed significant increases in expression of ADIPOR1 and ADIPOR2 when cells were treated with low RA index. Treatment with the different RA indexes did not impact on gene expression levels of PDX1 and INSR (Fig 3).

Discussion

The RA index and waist-to-hip ratio were revealed to be strongly associated with pancreatic beta-cell function. The in vitro studies support the relationship between the RA index and beta-cell function in terms of insulin secretion. Although previous results have shown the ratio to be a predictor of T2D development, to the best of our knowledge this is the first to report a direct relationship with pancreatic beta-cell function.

Dysregulation of adipokine secretion is frequently observed in obesity and T2D [28]. Circulating adiponectin in humans typically ranges between 2–30μg ml\(^{-1}\), while the serum concentration of resistin ranges from 7 to 22 ng ml\(^{-1}\) [29, 30]. Adiponectin has been associated with insulin sensitivity and metabolism of lipids in peripheral tissues [31, 32], along with stimulating insulin secretion [33]. Furthermore adiponectin has also been found to exert cytoprotective effects in beta-cells in vivo, and aids in protecting cells from undergoing apoptosis [27]. Resistin has been associated with insulin resistance and pro-inflammatory properties, along with impaired insulin secretion, and is believed to be an important link between obesity, insulin resistance and T2D [34, 35]. Resistin treatment impedes glucose tolerance and insulin response in mouse models [36], and modulates cell viability in cell lines [26]. However the translation of these findings to humans has been less conclusive, with mixed findings emerging [37, 38].
In support of our results a previous study identified that a resistin to adiponectin ratio was associated with T2D and Metabolic Syndrome (MS) risk [39]. Moreover, this study demonstrated that the ratio of resistin to adiponectin was more strongly correlated with insulin resistance indexes and key metabolic endpoints of T2D and MS than adiponectin and resistin levels alone. This together with our data support the role of the RA index as a potential biomarker of beta-cell function status; use of such a biomarker profile to identify persons at risk of development of T2D could be an important step in the development of targeted lifestyle interventions. Accurate assessment of beta-cell function from a fasting blood sample would allow for earlier identification of beta-cell dysfunction and make it easier to monitor an individual’s risk of progression into T2D.

Although the present cohort was generally healthy, 46 participants fell into an overweight and obese BMI category (>25 kg m\(^{-2}\)). Analysis between normal BMI and overweight and
Obese BMI categories revealed a significant decrease in both beta-cell function/HOMA-IR and DI as BMI increased. Importantly, an intervention study in 11 obese T2D individuals revealed that reducing BMI through energy restriction (600kcal/day) for 8 weeks resulted in significant improvements in beta-cell function [40]. A significant decrease in waist circumference (107.4 ± 2.2cm at baseline to 94.2 ± 2.5cm at week 8) was also observed in the intervention. Based on the present analysis, waist-to-hip ratio was a strong modulator of beta-cell function, when demographic and anthropometric variables were examined. Waist-to-hip ratio emerged as a stronger modulator of beta-cell function than BMI, which is interesting as it therefore may be a better indicator of T2D risk than a BMI score. Supporting evidence for this exists in the literature where waist-to-hip ratio was determined to be a stronger predictor than BMI of T2D risk in a small Taiwanese cohort [41]. This finding also adds to the hypothesis that central obesity and body shape may be important considerations when in assessing T2D risk, due to strong evidence that an excess of visceral fat is closely related to insulin resistance and T2D risk [13]. In a study by Bardini et al. (2011), a hypertriglyceridaemic waist phenotype (enlarged waist circumference and increased triglyceride levels) was associated with increased insulin resistance and an overexertion of beta-cell function in participants with normal glucose tolerance. While participants with impaired glucose tolerance and a hypertriglyceridaemic waist phenotype displayed a decrease in beta-cell function. This highlights the importance of implementing an early intervention to decrease T2D risk [42]. Ceramide 12:1(2H) was also predictive of beta-cell function in our cohort. Ceramides are suggested to be responsible for beta-cell apoptosis due to saturated fatty acid exposure, however the mechanism behind how ceramide accumulation leads to this is still unclear [43].

In vitro verification of the improved beta-cell functionality is an important aspect of this study: the low RA index significantly modulated acute insulin secretion. Functional assays revealed that there was a significant increase in plasma membrane potential in cells treated with the low RA index: this enhancement could underpin the increased insulin secretion under...
these conditions. Previous studies have examined alteration of plasma membrane potential of cells treated with adiponectin, with mixed findings. A study examining adiponectin treatment in pancreatic islets found no effects on membrane potential, however another study by Wen et al investigating adiponectin treatment in hypothalamic cells observed plasma membrane hyperpolarisation [44, 45]. In addition to alterations in the plasma membrane potential significant increases in ADIPOR1 and ADIPOR2 expression were observed following treatment with the low RA index. Adiponectin acts by binding and activating ADIPOR1 and ADIPOR2, and the increased expression of both receptors with low RA index treatment suggests that it plays a role in the regulation of beta-cell function [46, 47]. This increase in adiponectin receptor expression in conjunction with the alterations in plasma membrane potential provides a potential mechanism for the promotion of insulin secretion under these conditions.

Strengths of the present study include directly assessing factors related to specific beta-cell measures obtained during an OGTT and confirmation in an independent cohort.

Fig 3. Gene expression analysis of BRIN-BD11 cells treated with RA index. Low RA index significantly increases (A) ADIPOR1 and (B) ADIPOR2 mRNA expression in BRIN-BD11 cells. (C) No effect on INSR expression was observed when cells were treated with high and low RA index. (D) PDX1 expression was not altered by high or low RA index treatment. Experiments n = 6, *p < 0.05 versus the respective control.

doi:10.1371/journal.pone.0161350.g003
results mirrored the findings in the human studies and provided an opportunity to examine potential mechanisms by which the RA index promoted insulin secretion. Validation of the RA index in the FHI human cohort, a cohort slightly older and with a greater BMI than the MECHE cohort, also strengthens the case of the RA index as a factor related to beta-cell function. The present study population is limited to Irish participants and it is acknowledged that expansion of this research to non-Irish and non-European cohorts would be beneficial in order to fully translate the research findings to the global population.

Conclusions

In conclusion, our findings indicate that waist-to-hip ratio and RA index are strong factors related to pancreatic beta-cell function. Establishing whether alterations in the RA index is a causative factor in development of T2D is a question which remains to be answered. Furthermore, investigation of the ability to modify the RA index through lifestyle interventions will be key to the potential use of such an index. Future work will examine potential mechanisms for modulating the RA index which in turn may lead to new routes/interventions for improving beta-cell function.

Supporting Information

S1 Fig. The effect of 24 hour treatment with different RA indices on insulin secretion in BRIN-BD11 cell line. Values are mean ± standard deviation (n = 4). *p < 0.05 **p < 0.01 ***p < 0.001. ANOVA was applied across groups with post-hoc LSD test for comparison of various RA indexes with no treatment (control). Cells were incubated for 24 hours with no treatment (control), 0.1 ratio (5ng ml⁻¹ resistin and 50nmol l⁻¹ g-adiponectin), 0.5 ratio (10ng ml⁻¹ resistin and 20nmol l⁻¹ g-adiponectin), 1.0 ratio (10ng ml⁻¹ resistin, 10nmol l⁻¹ g-adiponectin), 2.0 ratio (20ng ml⁻¹ resistin, 10nmol l⁻¹ g-adiponectin), 4.0 ratio (20ng ml⁻¹ resistin, 5nmol l⁻¹ g-adiponectin) and then stimulated with 16.7mM glucose + 10mM alanine to determine insulin secretion. Overall p-value = 0.000053 (DOCX).

S2 Fig. The effect of RA index on changes in mitochondrial membrane potential. BRIN-BD11 cells were treated for 24 h with a control (no treatment), high RA index (20ng ml⁻¹ resistin, 5nmol l⁻¹ g-adiponectin) and a low RA index (10ng ml⁻¹ resistin, 10nmol l⁻¹ g-adiponectin). Cells were stimulated with 16.7mM glucose + 10mM alanine at 50 seconds and mitochondrial membrane potential was assessed. Data was analysed by determining the difference in relative fluorescence units (RFU) between the average baseline and post stimulation values for each experiment (delta change %). The decrease in fluorescence (normalised to baseline) upon stimulation was 18.9% for control, 21.8% for high RA index and 20.7% for low RA index. No statistically significant differences exist upon the decrease in RFU between control treatment and high and low RA index (overall ANOVA p = 0.758). Values are represented as mean values (n = 4). (DOCX)

S3 Fig. The effect of RA index on changes on intracellular calcium. BRIN-BD11 cells were treated for 24 h with a control (no treatment), high RA index (20ng ml⁻¹ resistin, 5nmol l⁻¹ g-adiponectin) and a low RA index (10ng ml⁻¹ resistin, 10nmol l⁻¹ g-adiponectin). Cells were stimulated with 16.7mM glucose + 10mM alanine at 100 seconds and intracellular calcium was assessed. Data was analysed by determining the difference in relative fluorescence units (RFU) between the average baseline and post stimulation values for each experiment (delta change %). The increase in fluorescence (normalised to baseline) upon stimulation was 44.3% for
control, 40.2% for high RA index and 46.1% for low RA index. No statistically significant differences exist upon the increase in RFU between control treatment and high and low RA index (overall ANOVA p = 0.728). Values are represented as mean values (n = 4).

S1 Table. List of ceramides from MECHE lipidomic dataset. CER: ceramide. List of ceramides measured in MECHE serum samples.

S2 Table. Linear regression of anthropometric, biochemical and ceramide data against additional beta-cell function measures. Summary of strongest predictors of beta-cell function using linear regression analysis. WHR, waist-to-hip ratio; HDL, high density lipoprotein cholesterol; RA index, resistin-to-adiponectin ratio; cer, ceramide. Data are presented as beta coefficient and P-value according to disposition index, using C-peptide data (nmol mmol⁻¹); beta-cell function using C-peptide (glucose in mmol l⁻¹, c-peptide in nmol l⁻¹) adjusted for the Matsuda index; P-value determined using backward linear regression analysis. Significance level = P < 0.05. Demographic and Anthropometric variables included were: age, sex, BMI, WHR, BP SYS, BP DIA. Biochemical variables included were: HDL cholesterol, adiponectin, resistin, RA index, triacylglycerides, Apo E, TNFα, IFNγ, IL2, IL4, IL6, IL8, IL10. Ceramide data from lipidomic analysis was examined. RA index in combination with IL-8 was significant predictor of beta-cell function (C-peptide) Matsuda index using linear regression (p = 0.043).

S3 Table. Baseline characteristics FHI cohort (n = 47). All values are means ± standard deviation. BMI, Body Mass Index; BP SYS, Systolic Blood Pressure; BP DIA, Diastolic Blood Pressure; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; BCF/HOMA-IR, beta-cell function adjusted by HOMA-IR; BCF”Matsuda index; beta-cell function adjusted by the Matsuda index (where glucose mg dl⁻¹ and insulin μIU ml⁻¹) RA index, resistin to adiponectin ratio.

Acknowledgments

Special thanks are due to Victoria O’Sullivan for assistance with in vitro experiments, Catherine Moss and the Conway Institute Core Facility for assistance with PCR experiments and analysis, and also participants of both the MECHE and FHI studies.

Author Contributions

Conceptualization: AC LB.
Data curation: AC MR.
Formal analysis: AC LB.
Funding acquisition: HMR EG MG LB.
Investigation: AC HMR EG MG MR ED LB.
Methodology: AC LB.
Project administration: MR LB.
Supervision: LB.
References

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94(3):311–21. Epub 2011/11/15. doi: 10.1016/j.diabres.2011.10.029 PMID: 22079683.

2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003; 46(1):3–19. Epub 2003/03/15. doi: 10.1007/s00125-002-1009-0 PMID: 12637977.

3. Elbein SC, Wegner K, Kahn SE. Reduced beta-cell compensation to the insulin resistance associated with obesity in members of caucasian familial type 2 diabetic kindreds. Diabetes Care. 2000; 23 (2):221–7. Epub 2000/06/27. PMID: 10868835.

4. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000; 49(11):1751–60. Epub 2000/11/15. PMID: 11078440.

5. Khalti MZ, Guiot Y, Gilon P, Henquin JC, Jonas JC. Increased glucose sensitivity of both triggering and amplifying pathways of insulin secretion in rat islets cultured for 1 wk in high glucose. Am J Physiol Endocrinol Metab. 2004; 287(2):E207–17. Epub 2004/04/22. doi: 10.1152/ajpendo.00426.2003 PMID: 15100093.

6. Nenquin M, Szollosi A, Aguilar-Bryan L, Bryan J, Henquin JC. Both triggering and amplifying pathways contribute to fuel-induced insulin secretion in the absence of sulfonylurea receptor-1 in pancreatic beta-cells. J Biol Chem. 2004; 279(31):32316–24. Epub 2004/06/04. doi: 10.1074/jbc.M402076200 PMID: 15175349.

7. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001; 50(1):150–8. Epub 2001/01/09. PMID: 11147781.

8. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004; 53 Suppl 3:S16–21. Epub 2004/11/25. PMID: 15561905.

9. Armlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011; 34(1):61–5. Epub 2010/09/21. doi: 10.2337/dc10-0955 PMID: 20852030; PubMed Central PMCID: PMCPMC3005442.

10. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007; 30(6):1562–6. Epub 2007/03/21. doi: 10.2337/dc06-2544 PMID: 17372155.

11. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2006; 84(2):427–33. Epub 2006/08/10. PMID: 16895894.

12. Donin AS, Nightingale CM, Owen CG, Rudnicka AR, Jebb SA, Ambrosini GL, et al. Dietary energy intake is associated with type 2 diabetes risk markers in children. Diabetes Care. 2014; 37(1):116–23. Epub 2013/08/14. doi: 10.2337/dc13-1263 PMID: 23939542; PubMed Central PMCID: PMCPMC3966263.

13. Carr DB, Utschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004; 53(8):2087–94. Epub 2004/07/28. PMID: 15277390.

14. Kruit JK, Brunham LR, Vercrhe CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol. 2010; 21(3):178–85. Epub 2010/05/14. doi: 10.1097/MOL.0b013e328339387b PMID: 20463468.

15. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012; 11:132. Epub 2012/10/11. doi: 10.1186/1476-511x-11-132 PMID: 23046637; PubMed Central PMCID: PMCPmc359971.

16. Bardini G, Dicembrini I, Rotella CM, Giannini S. Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance. Acta Diabetol. 2013; 50(2):277–81. Epub 2011/10/15. doi: 10.1007/s00592-011-0339-0 PMID: 21997326.

17. Kuo T, Kim-Muller JY, McGraw TE, Accili D. Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic beta Cell Dysfunction. J Biol Chem. 2016. Epub 2016/02/27. doi: 10.1074/jbc. M115.702163 PMID: 26917725.
18. O’Gorman A, Morris C, Ryan M, O’Grada CM, Roche HM, Gibney ER, et al. Habitual dietary intake impacts on the lipidomic profile. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 966:140–6. Epub 2014/02/26. doi: 10.1016/j.jchromb.2014.01.032 PMID: 24565891.

19. Morris C, O’Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, et al. Identification of differential responses to an oral glucose tolerance test in healthy adults. PLoS One. 2013; 8(8):e72890. Epub 2013/08/31. doi: 10.1371/journal.pone.0072890 PMID: 23991163; PubMed Central PMCID: PMCPmc3749984.

20. Wallace M, Morris C, O’Grada CM, Ryan M, Dillon ET, Coleman E, et al. Relationship between the lipidome, inflammatory markers and insulin resistance. Mol Biosyst. 2014; 10(1):1586–95. Epub 2014/04/10. doi: 10.1039/c3mb70529c PMID: 24714806.

21. Ryan MF, O’Grada CM, Morris C, Segurado R, Walsh MC, Gibney ER, et al. Within-person variation in the postprandial lipemic response of healthy adults. Am J Clin Nutr. 2013; 97(2):261–7. Epub 2013/01/04. doi: 10.3945/ajcn.112.047936 PMID: 23283501.

22. Utschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2009; 32(2):335–41. Epub 2008/10/30. doi: 10.2337/dc08-1478 PMID: 18957530; PubMed Central PMCID: PMCPmc2628704.

23. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22(9):1462–70. Epub 1999/09/10. PMID: 10480510.

24. McLennaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O’Harte FP, Yoon TW, et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electofusion. Diabetes. 1996; 45(8):1132–40. Epub 1996/08/01. PMID: 8690162.

25. Wallace M, Whelan H, Brennan L. Metabolomic analysis of pancreatic beta cells following exposure to high glucose. Biochim Biophys Acta. 2013; 1830(3):2583–90. Epub 2012/11/17. doi: 10.1016/j.bbagen.2012.10.025 PMID: 23153994.

26. Brown JE, Onyango DJ, Dunmore SJ. Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett. 2007; 581(17):3273–6. Epub 2007/06/29. doi: 10.1016/j.febslet.2007.06.031 PMID: 17957619.

27. Brown JE, Conner AC, Digby JE, Ward KL, Ramanjaneya M, Randeva HS, et al. Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin. Peptides. 2010; 31 (5):944–9. Epub 2010/02/17. doi: 10.1016/j.peptides.2010.02.004 PMID: 20156502.

28. Fiehmig G, Scholz M, Kloting N, Fasshauer M, Tonjes A, Stumvoll M, et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One. 2014; 9(6): e99785. Epub 2014/06/27. doi: 10.1371/journal.pone.0099785 PMID: 24968096; PubMed Central PMCID: PMCPmc4072672.

29. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79–83. Epub 1999/03/27. PMID: 10092513.

30. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012; 165(3):622–32. Epub 2011/05/07. doi: 10.1111/j.1476-5381.2011.01369.x PMID: 21545576; PubMed Central PMCID: PMCPmc3515035.

31. Tao C, Sifuentes A, Holland WL. Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic beta cells and adipocytes. Best Pract Res Clin Endocrinol Metab. 2014; 28 (1):43–58. Epub 2014/01/15. doi: 10.1016/j.beem.2013.11.003 PMID: 24417945; PubMed Central PMCID: PMCPmc4455885.

32. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramide activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011; 17(1):55–63. Epub 2010/12/28. doi: 10.1038/nm.2277 PMID: 21186369; PubMed Central PMCID: PMCPmc3134999.

33.Winzell MS, Nogueiras R, Dieguez C, Ahren B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun. 2004; 321(1):154–60. Epub 2004/09/11. doi: 10.1016/j.bbrc.2004.06.130 PMID: 15358228.

34. Benomar M, Gertler A, De Lacy P, Crepin D, Ould Hamouda H, Rioufaut L, et al. Central resistin overexpression induces insulin resistance through Toll-like receptor 4. Diabetes. 2013; 62(1):102–14. Epub 2012/09/11. doi: 10.2337/db12-0237 PMID: 22961082; PubMed Central PMCID: PMCPmc3526022.

35. Nakata M, Okada T, Ozawa K, Yada T. Resistin induces insulin resistance in pancreatic islets to impair glucose-induced insulin release. Biochem Biophys Res Commun. 2007; 353(4):1046–51. Epub 2007/01/09. doi: 10.1016/j.bbrc.2006.12.134 PMID: 17207771.
36. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818):307–12. Epub 2001/02/24. doi:10.1038/35053000 PMID: 11201732.

37. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab J. 2013; 37(6):404–14. Epub 2014/01/10. doi: 10.4093/dmj.2013.37.6.404 PMID: 24404511; PubMed Central PMCID: PMCPmc3881324.

38. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med. 2008; 149(5):307–16. Epub 2008/09/04. PMID: 18765700; PubMed Central PMCID: PMCPmc3874083.

39. Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovasc Diabetol. 2011; 10:8. Epub 2011/01/22. doi:10.1186/1475-2840-10-8 PMID: 21251282; PubMed Central PMCID: PMCPmc3036610.

40. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011; 54(10):2506–14. Epub 2011/09/04. doi:10.1007/s00125-011-2204-7 PMID: 21656330; PubMed Central PMCID: PMCPmc3188743.

41. Cheng CH, Ho CC, Yang CF, Huang YC, Lai CH, Liaw YP. Waist-to-hip ratio is a better anthropometric index than body mass index for predicting the risk of type 2 diabetes in Taiwanese population. Nutr Res. 2010; 30(9):585–93. Epub 2010/10/12. doi:10.1016/j.nutres.2010.08.007 PMID: 20934999.

42. Bardi G, Dicembrini I, Paia L, Cresci B, Rotella CM. Hypertriglyceridaemic waist phenotype and beta-cell function in subjects with normal and impaired glucose tolerance. Diabet Med. 2011; 28(10):1229–33. Epub 2011/09/20. doi:10.1111/j.1464-5491.2011.03332.x PMID: 21923697.

43. Boslem E, Meikle PJ, Biden TJ. Roles of ceramide and sphingolipids in pancreatic beta-cell function and dysfunction. Islets. 2012; 4(3):177–87. Epub 2012/08/01. doi:10.4161/isl.20120 PMID: 22847494; PubMed Central PMCID: PMCPMC3442815.

44. Okamoto M, Ohara-Imaizumi M, Kubota N, Hashimoto S, Eto K, Kanno T, et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetes. 2008; 57(5):827–35. Epub 2008/03/29. doi:10.2337/db07-1512 PMID: 18369586.

45. Wen JP, Lv WS, Yang J, Nie AF, Cheng XB, Yang Y, et al. Globular adiponectin inhibits GnRH secretion from GT1-7 hypothalamic GnRH neurons by induction of hyperpolarization of membrane potential. Biochem Biophys Res Commun. 2008; 371(4):756–61. Epub 2008/04/09. doi:10.1016/j.bbrc.2008.04.146 PMID: 18466765.

46. Yamashita T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423(6941):762–9. Epub 2003/06/13. doi: 10.1038/nature01705 PMID: 12802337.

47. Kharroubi I, Rasschaert J, Eizirik DL, CNop M. Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun. 2003; 312(4):1118–22. Epub 2003/12/04. PMID: 14651988.